ProCE Banner Activity

Management of Atopic Dermatitis in Primary Care and Specialty Settings

Podcast Episodes

In this podcast episode, leading dermatology experts, Dr Jonathan Silverberg and Ms Victoria Garcia-Albea discuss their experiences with novel agents and their place in therapy for moderate to severe atopic dermatitis (AD).

Released: July 19, 2022

Expiration: July 18, 2023

No longer available for credit.



Victoria Garcia-Albea

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN

Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Jonathan I. Silverberg

Jonathan I. Silverberg, MD, PhD, MPH

Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC


This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Provided by

ProCE Banner


Regeneron Pharmaceuticals

Sanofi Genzyme

Target Audience

Dermatology, primary care, and pediatric NPs and PAs

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate a co-management approach with shared decision-making into patient and caregiver encounters

  • Select appropriate therapies for pediatric and adult patients with moderate to severe AD based on patient- and disease-related factors and the efficacy and safety of available therapies


Victoria Garcia-Albea: consultant: Sanofi-Genzyme.

Jonathan Silverberg: consultant: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Sidekick Health; fees for non-CME/CE services: AbbVie, Eli Lilly, Leo, Pfizer, Regeneron, Sanofi; funds for research support (paid to institution): Galderma, Pfizer.



Additional Information

Program Medium

This program has been made available online.